약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 5.

Table. 5. Spending trends of Economic Evaluation Exemption drugs among RSA listed high-priced medicines by drug characteristics (unit: 1,000,000 KRW)
Category 2016 2018 2020 2021 (%)
Total EEE 10,082 61,981 134,424 161,018 (100.0%)
Cost per patient
Low 5,300 38,018 60,425 88,834 (55.2%)
Middle 13,914 21,391 19,478 (12.1%)
High 353 38,193 (23.7%)
Extra high 4,783 10,049 52,255 14,513 ( 9.0%)
ATC category
A16A 4,783 11,553 12,129 14,513 (9.0%)
B01A 3,423 7,583 6,597 (4.1%)
L01E 2,818 16,435 26,669 31,685 (19.7%)
L01F 2,482 21,969 26,805 37,839 (23.5%)
L01X 7,274 14,861 25,476 (15.8%)
L04A 1,327 2,475 3,254 (2.0%)
M09A 42,452 38,193 (23.7%)
N07X 1,450 1,848 (1.1%)
V10X 1,614 (1.0%)
Proportion of anti-cancer drugs1)
52.6% 73.7% 50.8% 59.0%

1) Anti-cancer drugs include L01E, L01F, and L01X.

Yakhak Hoeji 2023;67:388-97 https://doi.org/10.17480/psk.2023.67.6.388
© 2023 Yakhak Hoeji